Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women

Trial Profile

Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Letrozole (Primary) ; Palbociclib (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 negative breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms NeoPAL
  • Sponsors UNICANCER

Most Recent Events

  • 22 Mar 2022 Results (n=106) published in the European Journal of Cancer.
  • 04 Jun 2021 Status changed from active, no longer recruiting to completed.
  • 11 Sep 2020 This trial has been completed in Belgium, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top